Slide 1: Investor Presentation September 2017
For personal use only INVESTOR PRESENTATION SEPTEMBER 2017
Slide 2: Disclaimer
DISCLAIMER This investor presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 Future performance 949 739) (Cann) and comprises written material regarding Cann. This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "i
Slide 3: Disclaimer
DISCLAIMER All rights reserved Several photographs contained in this Presentation are the property of Cann and are protected For personal use only under copyright laws. No part of this Presentation may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, re
Slide 4: Company Snapshot (30/8/17)
COMPANY SNAPSHOT (30/8/17) 4 For personal use only METRIC VALUE 8 $1.60 Millions Share price $1.13 7 $1.40 6 $1.20 Shares on issue (fully diluted) 110.4m 5 $1.00 4 $0.80 Market capitalisation $124.7m 3 $0.60 2 IPO price ($0.30) $0.40 1 $0.20 Cash $13.4m 0 $- 4/05/2017 4/06/2017 4/07/2017 4/08/2017 E
Slide 5: 2017 Achievements
2017 ACHIEVEMENTS 5 For personal use only • Secured first licences (research & cultivation) in Australia from ODC • $13.5m raised in heavily supported IPO; listed on ASX 4 May • Southern facility expansion underway • Northern facility lease executed; commissioning due by end 2017 • Cann team growing
Slide 6: Company Overview
COMPANY OVERVIEW 6 For personal use only FOCUSED ON BREEDING & EXPERIENCED CULTIVATING MEDICINAL CANNABIS AGRIBUSINESS BOARD Cann is a vertically-integrated High profile & experienced Australian agribusiness company agribusiness board & focused on breeding, cultivating & management team manufacturin
Slide 7: Board & Management Team
BOARD & MANAGEMENT TEAM 7 For personal use only • Allan has extensive experience in the agribusiness • Experienced public company director sector as well as significant tenures with biotechnology • Co-founded Premier Artists & Frontier Touring Company companies • Very strong financial management bac
Slide 8: Capital Structure & Use of Funds
CAPITAL STRUCTURE & USE OF FUNDS 8 For personal use only ESTIMATED DESCRIPTION SPEND ($M) Construction of purpose-built facility 1.8 NO. OF TOTAL TOTAL DESCRIPTION Feasibility / scoping study for SHARES UNDILUTED DILUTED 0.5 purpose-built facility Total Issued Capital 108,353,336 100.0% 98.2% (ordin
Slide 9: R&D & Cultivation Program
R&D & CULTIVATION PROGRAM 9 PROGRESSING AHEAD OF SCHEDULE For personal use only Cann is progressing a three phase growth strategy to build its cultivation capability, with adequate funding to complete Phases 1 & 2 Southern facility’s Northern facility secured Phase 3 three additional indoor & commis
Slide 10: Our Focus
OUR FOCUS 1 0 For personal use only Rapidly developing Regulatory market with substantial pathway now A clear growth potential defined Australian focus CANN IS UNIQUELY FOCUSED ON BUILDING A WORLD-CLASS AUSTRALIAN-BASED MEDICINAL CANNABIS COMPANY Licences & permits Accelerating cultivation Key indus
Slide 11: Regulatory Pathway
REGULATORY PATHWAY 1 1 For personal use only Source: Australian Government Department of Health / Therapeutic Goods Administration
Slide 12: Business Model & the Industry Value Chain
BUSINESS MODEL & THE INDUSTRY VALUE CHAIN 1 2 For personal use only FEDERAL & STATE GOVERNMENT REGULATED …with a clear pathway to secure Cann’s competitive strengths lie in these segments of the value chain… involvement in these segments Clinical Cultivation & Packaging & Research & Development Manu
Slide 13: Growth Cycle
GROWTH CYCLE 1 3 For personal use only 18-24 hours light per day Less than 12 hours light per day 6-9 week duration Cuttings every two weeks Mother plants Flowering Propagation Vegetative Re-pot 10-14 days 21-28 days Re-pot
Slide 14: The Opportunity: Australian Market Size
THE OPPORTUNITY: AUSTRALIAN MARKET SIZE 14 Forecasting the potential size of the Australian medicinal cannabis market can be roughly determined using two methodologies For personal use only Methodology 1: Demand-driven by condition Methodology 2: Peer country comparable usage • Australia only – allo
Slide 15: Australian Industry Leader
AUSTRALIAN INDUSTRY LEADER 1 5 Established operations For personal use only Various images from recent propagation, cultivation & • Secure Cultivation Rooms fitted with requisite lighting, irrigation, climate harvest at Cann’s control & other equipment to grow cannabis for medicinal & research relat
Slide 16: Licensing & Distribution Agreement with CannaKorp
LICENSING & DISTRIBUTION AGREEMENT WITH CANNAKORP 1 6 For personal use only Cann has executed a licensing & distribution agreement with Massachusetts-based technology start-up CannaKorp • Cann secures agreement to import & sell CannaKorp’s proprietary vaporizing system in Australia & NZ • Secures ri
Slide 17: Cornerstone Investor: Aurora Cannabis Inc.
CORNERSTONE INVESTOR: AURORA CANNABIS 1 INC. 7 Aurora Cannabis Inc. (TSXV:ACB), one of Canada’s largest publicly-listed cannabis companies, For personal use only holds a 19.9% shareholding in Cann after investing A$6.5m in the IPO METRIC VALUE • Canada’s 2nd largest (by market capitalisation) public
Slide 18: Milestones & Newsflow
MILESTONES & NEWSFLOW 18 For personal use only 2018 Development of IP portfolio Targeting & securing research grants with various NGOs & industry bodies, such as Pain First revenues with commencement Australia, AFAO (AIDS/HIV), of clinical trial Epilepsy Foundation, etc Each state identifying/giving
Slide 19: Contacts
CONTACTS For personal use only INVESTOR / MEDIA RELATIONS Peter Crock Matthew Wright Cann Group Limited NWR Communications Pty Ltd Ph: +61 (0)3 9095 7088 Ph: +61 (0)451 896 420 E: contact@canngrouplimited.com E: matt@nwrcommunications.com.au
Slide 20: For personal use only
srsonal use only. ‘NY =Ok CANN